abstract |
FIELD: chemistry. n SUBSTANCE: invention provides crystalline solid form of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalin-2-ylamino)-2-cyclohexylmethyl-butyric acid or crystalline hydrochloride of (S)-4-((2S,3S)-7-carbamoyl-1,1-diethyl-3-methoxy-1,2,3,4-tetrahydronaphthalin-2-ylamino)-2-cyclohexylmethyl-butyric acid. Invention relates to pharmaceutical composition, possessing antagonistic activity with respect to mu-opioid receptor, which contains therapeutically effective quality of crystalline solid form. n EFFECT: invention provides methods of applying claimed crystalline solid forms in treatment of diseases associated with activity of mu-opioid receptors and methods of obtaining claimed crystalline solid forms. n 27 cl, 9 dwg, 17 ex |